Madison Vaccines, Inc. logo

Madison Vaccines, Inc.

Madison Vaccines Incorporated (MVI) is a clinical stage biopharmaceutical company developing plasmid DNA immunotherapy for prostate cancer patients.

MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.madisonvaccinesinc.com
Founded2012
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
505 South Rosa Road Suite 201,WI,53719
Madison
United States
Email
Contact Number
+1 646-237-6926

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Madison vaccines are designed to re-activate the bodys own immune system to kill prostate tumors. MVI plasmid DNA vaccines are delivered to patients by simple intradermal injection According to Madison, compared with protein or peptide vaccines, plasmid DNA vaccines are cheaper and faster to manufacture, avoid solubility issues, and are more stable in storage.

In Jan 2014, Madison closed an $8 Mn Series A financing round led by Madison-based Venture Investors, joined by the Wisconsin Alumni Research Foundation (WARF), the State of Wisconsin Investment Board.